黄芪及其制剂治疗糖尿病的药理及机制研究新进展
New Advances in Pharmacological and Mechanistic Studies on the Treatment of Diabetes with Astragalus and Its Preparations
DOI: 10.12677/acm.2025.15113109, PDF,   
作者: 王艺晴, 李佳睿, 李嘉懿, 李 娟：黑龙江中医药大学研究生院，黑龙江 哈尔滨；杜丽坤*：黑龙江中医药大学附属第一医院内分泌二科，黑龙江 哈尔滨
关键词: 黄芪；糖尿病；黄芪多糖；黄芪皂苷；参芪降糖颗粒；Astragalus membranaceus； Diabetes； Astragalus Polysaccharides； Astragalus Saponins； Shenqi Jiangtang Granules
摘要: 传统中药黄芪及其制剂在临床应用中覆盖面广泛，尤其在治疗糖尿病(DM)方面展现出显著疗效。其活性成分黄芪多糖具备降低胰岛素抵抗、保护胰岛β细胞、免疫调节、抗炎、抗氧化以及调节肠道菌群等多重功效；黄芪皂苷则具有降血糖、降血脂等重要作用；黄芪多酮更在治疗糖尿病视网膜病变方面展现出潜在价值。此外，黄芪制剂如参芪降糖颗粒、消渴丸、金芪降糖片等，在改善胰岛素抵抗、降血糖、抗炎、抗氧化等方面同样效果显著。
Abstract: Traditional Chinese medicine Astragalus membranaceus and its preparations have a wide range of clinical applications, especially showing significant efficacy in the treatment of diabetes mellitus (DM). Its active component, Astragalus polysaccharides, possesses multiple functions such as reducing insulin resistance, protecting pancreatic β cells, immune regulation, anti-inflammation, antioxidation, and regulating intestinal flora; astragalosides play an important role in lowering blood sugar and blood lipids; astragalosides also show potential value in the treatment of diabetic retinopathy. In addition, Astragalus preparations such as Shenqi Jiangtang Granules, Xiaoke Pills, and Jinqi Jiangtang Tablets are also significantly effective in improving insulin resistance, lowering blood sugar, anti-inflammation, and antioxidation.
文章引用：王艺晴, 李佳睿, 李嘉懿, 李娟, 杜丽坤. 黄芪及其制剂治疗糖尿病的药理及机制研究新进展[J]. 临床医学进展, 2025, 15(11): 381-388. https://doi.org/10.12677/acm.2025.15113109

参考文献

[1] 杨叔禹. 国家糖尿病基层中医防治管理指南(2022) [J]. 中医杂志, 2022, 63(24): 2397-2414.
[2] 朱凡凡, 章亚平, 王珍. 国内外糖尿病疾病管理研究进展[J]. 循证护理, 2017, 3(6): 592-594.
[3] 姚文强, 王旭, 张擎. 论糖尿病中医三防观[J]. 河北中医, 2024, 46(11): 1890-1894.
[4] 董立, 丛绍强, 程明丽, 等. 中药黄芪的药理作用分析及临床应用效果[J]. 中国卫生标准管理, 2024, 15(11): 126-130.
[5] 李曼, 李孝波. 基于《神农本草经》《金匮要略》浅谈仲景用黄芪[J/OL]. 中医临床研究, 2025, 17(21): 74-77.
http://kns.cnki.net/kcms/detail/11.5895.R.20240930.1405.004.html, 2024-12-10.
[6] 吴艳梅, 陈永华, 徐寒松, 等. 黄芪多糖抗2型糖尿病的研究进展[J]. 云南中医中药杂志, 2024, 45(9): 94-98.
[7] 周书敏, 朱美蓉, 冯晓丹. 黄芪治疗糖尿病的临床进展[J]. 现代医学与健康研究电子杂志, 2024, 8(17): 130-133.
[8] 何嘉郡, 秦晨, 贺廉清, 等. 黄芪黄酮类成分及其药理作用研究[J]. 辽宁中医药大学学报, 2024, 26(1): 112-119.
[9] 刁元元, 李玉梅, 李晓文, 等. 黄芪抗糖尿病并发症的研究进展[J]. 中国比较医学杂志, 2021, 31(4): 123-128.
[10] Wang, J., Wang, C., Li, S., Li, W., Yuan, G., Pan, Y., et al. (2017) Anti-Diabetic Effects of Inonotus Obliquus Polysaccharides in Streptozotocin-Induced Type 2 Diabetic Mice and Potential Mechanism via PI3K-Akt Signal Pathway. Biomedicine & Pharmacotherapy, 95, 1669-1677. [Google Scholar] [CrossRef] [PubMed]
[11] James, D.E., Stöckli, J. and Birnbaum, M.J. (2021) The Aetiology and Molecular Landscape of Insulin Resistance. Nature Reviews Molecular Cell Biology, 22, 751-771. [Google Scholar] [CrossRef] [PubMed]
[12] Ke, B., Ke, X., Wan, X., Yang, Y., Huang, Y., Qin, J., Hu, C. and Shi, L. (2017) Astragalus Polysaccharides Attenuates TNF-α-Induced Insulin Resistance via Suppression of miR-721 and Activation of PPAR-γ and PI3K/AKT in 3T3-L1 Adipocytes. American Journal of Translational Research, 9, 2195-2206.
[13] Ye, Y., Deng, T., Wan, X., Ouyang, J., Liu, M. and Mao, X. (2013) The Role of Quantitative Changes in the Epxression of Insulin Receptor Substrate-1 and Nuclear Ubiquitin in Abnormal Glycometabolism in the Livers of Kkay Mice and the Relative Therapeutic Mechanisms of Astragalus Polysaccharide. International Journal of Molecular Medicine, 33, 341-350. [Google Scholar] [CrossRef] [PubMed]
[14] Li, Q., Yin, W., Cai, M., Liu, Y., Hou, H., Shen, Q., et al. (2009) NO-1886 Suppresses Diet-Induced Insulin Resistance and Cholesterol Accumulation through Stat5-Dependent Upregulation of IGF1 and Cyp7a1. Journal of Endocrinology, 204, 47-56. [Google Scholar] [CrossRef] [PubMed]
[15] Yue, X., Hao, W., Wang, M. and Fu, Y. (2023) Astragalus Polysaccharide Ameliorates Insulin Resistance in Hepg2 Cells through Activating the STAT5/IGF‐1 Pathway. Immunity, Inflammation and Disease, 11, e1071. [Google Scholar] [CrossRef] [PubMed]
[16] Liu, M., Qin, J., Hao, Y., Liu, M., Luo, J., Luo, T., et al. (2013) Astragalus Polysaccharide Suppresses Skeletal Muscle Myostatin Expression in Diabetes: Involvement of ROS-ERK and NF-κB Pathways. Oxidative Medicine and Cellular Longevity, 2013, Article ID: 782497. [Google Scholar] [CrossRef] [PubMed]
[17] Zheng, Y., Ren, W., Zhang, L., Zhang, Y., Liu, D. and Liu, Y. (2020) A Review of the Pharmacological Action of Astragalus Polysaccharide. Frontiers in Pharmacology, 11, Article No. 349.
[18] Deng, S., Yang, L., Ma, K. and Bian, W. (2021) Astragalus Polysaccharide Improve the Proliferation and Insulin Secretion of Mouse Pancreatic β Cells Induced by High Glucose and Palmitic Acid Partially through Promoting miR-136-5p and miR-149-5p Expression. Bioengineered, 12, 9872-9884. [Google Scholar] [CrossRef] [PubMed]
[19] Lu, J., Chen, X., Zhang, Y., Xu, J., Zhang, L., Li, Z., et al. (2013) Astragalus Polysaccharide Induces Anti-Inflammatory Effects Dependent on AMPK Activity in Palmitate-Treated RAW264.7 Cells. International Journal of Molecular Medicine, 31, 1463-1470. [Google Scholar] [CrossRef] [PubMed]
[20] Li, C., Liu, Y., Zhang, Y., Li, J. and Lai, J. (2022) Astragalus Polysaccharide: A Review of Its Immunomodulatory Effect. Archives of Pharmacal Research, 45, 367-389. [Google Scholar] [CrossRef] [PubMed]
[21] Mallone, R. and van Endert, P. (2008) T Cells in the Pathogenesis of Type 1 Diabetes. Current Diabetes Reports, 8, 101-106. [Google Scholar] [CrossRef] [PubMed]
[22] Liu, S., Wang, L., Zhang, Z., Leng, Y., Yang, Y., Fu, X., et al. (2024) The Potential of Astragalus Polysaccharide for Treating Diabetes and Its Action Mechanism. Frontiers in Pharmacology, 15, Article ID: 1339406. [Google Scholar] [CrossRef] [PubMed]
[23] 黎国英, 喻巍, 李策, 等. 黄芪多糖对糖尿病大鼠视网膜炎症因子表达水平及神经细胞氧化损伤的影响[J]. 中华生物医学工程杂志, 2017, 23(2): 111-116.
[24] 裴文丽. 黄芪多糖对2型糖尿病大鼠血清IL-1β、IL-6、IL-18的影响作用[J]. 中医临床研究, 2016, 8(2): 10-13.
[25] Han, J., Guo, D., Sun, X., Wang, J., Ouyang, J. and Gui, B. (2019) Repair Effects of Astragalus Polysaccharides with Different Molecular Weights on Oxidatively Damaged HK-2 Cells. Scientific Reports, 9, Article No. 9871. [Google Scholar] [CrossRef] [PubMed]
[26] Mohammadzadeh, N., Razavi, S., Hadi, Z., Kermansaravi, M., Boloori, S., Kabir, A., et al. (2020) Human Gut Microbiota and Its Possible Relationship with Obesity and Diabetes. International Journal of Diabetes in Developing Countries, 41, 235-243. [Google Scholar] [CrossRef] 
[27] Liu, J., Qiao, B., Deng, N., Wu, Y., Li, D. and Tan, Z. (2023) The Diarrheal Mechanism of Mice with a High-Fat Diet in a Fatigued State Is Associated with Intestinal Mucosa Microbiota. 3 Biotech, 13, Article No. 77. [Google Scholar] [CrossRef] [PubMed]
[28] Chen, X., Chen, C. and Fu, X. (2022) Hypoglycemic Effect of the Polysaccharides from Astragalus membranaceus on Type 2 Diabetic Mice Based on the “Gut Microbiota-Mucosal Barrier”. Food & Function, 13, 10121-10133. [Google Scholar] [CrossRef] [PubMed]
[29] Li, L., Zhang, Y., Luo, Y., Meng, X., Pan, G., Zhang, H., et al. (2023) The Molecular Basis of the Anti-Inflammatory Property of Astragaloside IV for the Treatment of Diabetes and Its Complications. Drug Design, Development and Therapy, 17, 771-790. [Google Scholar] [CrossRef] [PubMed]
[30] Zhou, X., Wang, L.L., Tang, W.J. and Tang, B. (2021) Astragaloside IV Inhibits Protein Tyrosine Phosphatase 1B and Improves Insulin Resistance in Insulin-Resistant HepG2 Cells and Triglyceride Accumulation in Oleic Acid (OA)-Treated HepG2 Cells. Journal of Ethnopharmacology, 268, Article ID: 113556. [Google Scholar] [CrossRef] [PubMed]
[31] Gong, P., Xiao, X., Wang, S., Shi, F., Liu, N., Chen, X., et al. (2023) Hypoglycemic Effect of Astragaloside IV via Modulating Gut Microbiota and Regulating AMPK/SIRT1 and PI3K/AKT Pathway. Journal of Ethnopharmacology, 281, Article ID: 114558.
[32] Lv, L., Wu, S.Y., Wang, G.F., Zhang, J.J., Pang, J.X., Liu, Z.Q., et al. (2009) Effect of Astragaloside IV on Hepatic Glucose‐Regulating Enzymes in Diabetic Mice Induced by a High‐Fat Diet and Streptozotocin. Phytotherapy Research, 24, 219-224. [Google Scholar] [CrossRef] [PubMed]
[33] Zhang, N., Wang, X., Mao, S. and Zhao, F. (2011) Astragaloside IV Improves Metabolic Syndrome and Endothelium Dysfunction in Fructose-Fed Rats. Molecules, 16, 3896-3907. [Google Scholar] [CrossRef] [PubMed]
[34] 马园园, 王静, 罗琼, 等. 黄芪总皂苷药理作用研究进展[J]. 辽宁中医药大学学报, 2020, 22(7): 153-157.
[35] Ma, L., La, X., Zhang, B., Xu, W., Tian, C., Fu, Q., et al. (2023) Total Astragalus Saponins Can Reverse Type 2 Diabetes Mellitus-Related Intestinal Dysbiosis and Hepatic Insulin Resistance in Vivo. Frontiers in Endocrinology, 14, Article ID: 1190827. [Google Scholar] [CrossRef] [PubMed]
[36] Dong, M., Li, J., Yang, D., Li, M. and Wei, J. (2023) Biosynthesis and Pharmacological Activities of Flavonoids, Triterpene Saponins and Polysaccharides Derived from Astragalus Membranaceus. Molecules, 28, Article No. 5018. [Google Scholar] [CrossRef] [PubMed]
[37] Wu, J., Ke, X., Ma, N., Wang, W., Fu, W., Zhang, H., et al. (2016) Formononetin, an Active Compound of Astragalus membranaceus (Fisch) Bunge, Inhibits Hypoxia-Induced Retinal Neovascularization via the HIF-1α/VEGF Signaling Pathway. Drug Design, Development and Therapy, 10, 3071-3081. [Google Scholar] [CrossRef] [PubMed]
[38] Li, T., Li, H., Wu, Y., Wu, Q., Zhao, G., Cai, Z., et al. (2021) Efficacy and Safety of Shenqi Jiangtang Granules plus Oral Hypoglycemic Agent in Patients with Type 2 Diabetes Mellitus: A Protocol for Systematic Review and Meta-Analysis of 15 RCTs. Medicine, 100, e23578. [Google Scholar] [CrossRef] [PubMed]
[39] Bai, L., Gao, J., Wei, F., Zhao, J., Wang, D. and Wei, J. (2018) Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes. Frontiers in Pharmacology, 9, Article No. 423. [Google Scholar] [CrossRef] [PubMed]
[40] Shi, S., Sun, M., Liu, Y., Jiang, J. and Li, F. (2022) Insight into Shenqi Jiangtang Granule on the Improved Insulin Sensitivity by Integrating in Silico and in Vivo Approaches. Journal of Ethnopharmacology, 282, Article ID: 114672. [Google Scholar] [CrossRef] [PubMed]
[41] Su, S., Guo, Z., Yang, H., Liu, H., Tang, J. and Jiang, X. (2025) Mechanism of Qizhi Jiangtang Capsule Inhibits Podocyte Pyroptosis to Improve Kidney Injury in Diabetes Nephropathy by Regulating NLRP3/Caspase-1/GSDMD Pathway. Chinese Journal of Cellular and Molecular Immunology, 41, 204-210.
[42] 张文诚. 消渴丸: 中西合璧的降糖“利器” [J]. 药物与人, 2025(5): 39-41.
[43] 丁雷. 基于转录组学整合分析《普济方》治消渴丸防治T2DM的机制研究[D]: [博士学位论文]. 北京: 北京中医药大学, 2024.
[44] 房丛丛. 金芪降糖片联合二甲双胍对新诊断2型糖尿病患者同型半胱氨酸, 胱抑素-C的影响[D]: [硕士学位论文]. 济南: 山东中医药大学, 2022.
[45] 杨洁. 观察金芪降糖片联合吡格列酮片治疗2型糖尿病高胰岛素血症的临床疗效[J]. 中国医药指南, 2014, 12(29): 7+9.
[46] 董方昕, 姚瑶, 毛浩洋, 等. 金芪降糖片组方中总黄酮提取工艺研究[J]. 化学工程师, 2024, 38(3): 92-95+87.

为你推荐